A vascular malformation is a structural abnormality of blood vessels or lymphatic channels that forms before birth and persists throughout life. Unlike vascular tumors, which grow because their cells multiply abnormally, vascular malformations are essentially plumbing errors: the vessels themselves are built wrong, with walls that are too thin, channels that are too wide, or connections that skip the normal capillary bed entirely. The International Society for the Study of Vascular Anomalies (ISSVA) draws this line clearly, classifying all vascular anomalies into either tumors (driven by cell proliferation) or malformations (driven by structural defects).1PubMed Central. ISSVA Classification of Vascular Anomalies and Molecular Biology That distinction matters more than it might seem, because the type of malformation determines everything from how quickly it grows to which drugs can treat it.
Why the Tumor-Malformation Distinction Matters
For decades, doctors lumped vascular tumors and vascular malformations together under vague labels like “hemangioma” or “birthmark,” which led to confused treatment plans and frustrated patients. The ISSVA classification system, most recently updated in 2018, sorts vascular anomalies into two clean categories based on biology rather than appearance. Vascular tumors involve endothelial cells that are actively dividing. The classic infantile hemangioma, for instance, grows rapidly in a baby’s first year and then slowly shrinks on its own. Vascular malformations, by contrast, do not involve abnormal cell growth. Their vessels are simply malformed from the start, and because the abnormal architecture is baked in, these lesions do not spontaneously disappear. They grow proportionally with the body and, in many cases, gradually worsen over time.
This is why someone told “it’s just a birthmark, they’ll grow out of it” may end up disappointed. A hemangioma often does resolve. A vascular malformation does not. Getting the classification right early changes whether a doctor takes a watchful-waiting approach or starts planning treatment.
Types Based on Flow Speed
Vascular malformations are grouped by what type of vessel is involved and, more practically, by how fast blood moves through them. The two broad camps are low-flow and high-flow malformations, and they behave quite differently.
Low-Flow Malformations
These involve veins, capillaries, lymphatic channels, or some combination. Blood moves through them slowly or pools within them, which creates its own set of problems.
- Capillary malformations: the most common type of vascular malformation. These are flat, pink-to-purple skin discolorations often called port-wine stains. Research has traced them to a somatic mutation in the GNAQ gene, which encodes a signaling protein involved in blood vessel development.2PubMed Central. A somatic missense mutation in GNAQ causes capillary malformation When that same GNAQ mutation affects vessels in the brain or eye, it can cause Sturge-Weber syndrome, a more serious condition involving seizures and glaucoma.3PubMed Central. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ
- Venous malformations: soft, compressible blue masses made of dilated, thin-walled veins. They swell when you bear down or hang the affected limb below your heart. Many are caused by mutations in the TIE2 receptor gene, which disrupts normal vessel wall formation and leads to defective vein architecture.4PubMed Central. Common and specific effects of TIE2 mutations causing venous malformations
- Lymphatic malformations: fluid-filled cysts or spongy masses that arise from malformed lymphatic channels. These tend to appear in the head, neck, or armpit. PIK3CA mutations have been identified in affected lymphatic tissue in roughly four out of five patients with isolated lymphatic malformations.5The Journal of Clinical Investigation. Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations
Combined malformations involving more than one vessel type also occur. A lesion with both venous and lymphatic components, for instance, is classified as a venolymphatic malformation and can be harder to treat than either type alone.
High-Flow Malformations
Arteriovenous malformations (AVMs) are the most clinically significant high-flow lesions. An AVM is a tangle of abnormal vessels, called a nidus, where arteries feed directly into veins without the normal capillary bed in between. This creates a high-flow, low-resistance shortcut between the arterial and venous systems.6PubMed Central. Brain arteriovenous malformations Because blood rushes through at arterial pressure, AVMs can cause a palpable pulse or a bruit (an audible whooshing sound), and in the brain, they carry a risk of hemorrhage. Extracranial AVMs, found in the face, limbs, or pelvis, tend to progress through stages: an initial quiet phase, followed by expansion, then pain and tissue destruction if left untreated.
Syndromic Presentations
Some vascular malformations appear as part of broader genetic syndromes rather than as isolated lesions. Klippel-Trénaunay syndrome, for example, combines a capillary malformation (typically a port-wine stain on a limb) with venous or lymphatic malformations and overgrowth of the soft tissue and bone in the affected limb.7PubMed Central. The Klippel-Trénaunay Syndrome in 2022: Unravelling Its Genetic and Molecular Profile and Its Link to the Limb Overgrowth Syndromes These syndromic forms overlap with the PIK3CA-related overgrowth spectrum (PROS), a group of conditions linked by shared genetic mutations. Understanding that an individual lesion sits within a syndrome can change the surveillance and treatment plan significantly, since the malformation may be just one piece of a systemic problem.
What Causes Them at the Genetic Level
Nearly all vascular malformations arise from somatic mutations, meaning they occur randomly in a cell during fetal development rather than being inherited from a parent. Because only some cells carry the mutation (a situation called mosaicism), the malformation is localized to a particular area of the body. The earlier the mutation happens during embryonic development, the larger and more widespread the malformation tends to be.
Researchers have now mapped many of these mutations to a handful of signaling pathways that control how blood and lymphatic vessels grow. Mutations that activate the PI3K/AKT/mTOR pathway are found in many venous, lymphatic, and combined malformations. Mutations in the RAS/MAPK pathway drive many AVMs and some capillary malformations.8PubMed. Genetic Basis and Therapies for Vascular Anomalies This genetic mapping has had an enormous practical payoff: because these same pathways are already targeted by existing cancer drugs, clinicians now have a growing menu of medications they can repurpose for vascular malformations that resist conventional treatment.
How Doctors Diagnose and Image Malformations
Diagnosis usually begins with a physical exam and a careful history. A soft, compressible blue mass that swells when a patient strains points toward a venous malformation. A flat, pink-purple stain present since birth is likely capillary. A pulsatile mass with a thrill suggests an AVM. But clinical impression alone is not enough for treatment planning.
Ultrasound with Doppler is typically the first imaging step. It distinguishes high-flow from low-flow lesions and gives a rough sense of size and depth. For a more detailed picture of how far a malformation extends and which structures it involves, MRI is the standard. CT angiography or MR angiography adds another layer when the vascular supply of a high-flow lesion needs to be mapped before a procedure.9PubMed Central. A Step-by-Step Sonographic Approach to Vascular Anomalies in the Pediatric Population: A Pictorial Essay
A newer and still-evolving diagnostic tool is the liquid biopsy. Researchers have shown that cell-free DNA carrying the causative mutation can be detected in a patient’s blood, which could eventually allow genetic diagnosis without surgery. In one study, KRAS mutations were picked up in blood drawn from the veins draining AVMs, with the concentration of mutant DNA jumping tenfold when the blood was sampled closer to the malformation itself.10PubMed Central. Malformations Cell-free DNA next-generation sequencing liquid biopsy as a new revolutionary approach for arteriovenous malformation For lymphatic malformations, PIK3CA mutations have been detected in cyst fluid at rates comparable to tissue-based sequencing, potentially sparing patients a biopsy.11Genetics in Medicine. Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations These approaches are not yet routine, but they are moving toward clinical use.
Sclerotherapy and Embolization
For low-flow malformations, sclerotherapy is often the first-line treatment. A doctor uses image guidance to inject a chemical agent directly into the abnormal vessels, causing them to scar shut and shrink. The choice of agent involves tradeoffs. Ethanol is the most potent sclerosant, achieving volume reductions of up to about 95%, but it carries a higher risk of complications like skin necrosis and nerve damage. Bleomycin produces more modest volume reductions, in the range of roughly 40 to 80%, but with fewer serious side effects.12PubMed Central. The Role of Bleomycin Sclerotherapy in Venous Malformation Management: A Narrative Review A newer formulation, bleomycin-polidocanol foam, appears to be comparably effective to ethanol with a trend toward fewer severe adverse events, though the difference has not reached statistical significance in published cohorts.13PubMed Central. Comparison of bleomycin polidocanol foam versus absolute ethanol for sclerotherapy of venous malformations
For high-flow AVMs, the approach shifts to embolization: blocking the feeding arteries or the nidus itself with materials delivered through a catheter. Liquid embolic agents like Onyx, a polymer that solidifies on contact with blood, are commonly used. Onyx forms a durable cast within the target vessel, plugging abnormal flow.14PubMed Central. Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology Older cyanoacrylate glues are still used in specific situations, such as when a macro-shunt needs to be sealed quickly. The newer copolymer agents have accumulated a large body of safety and efficacy data for cerebral vascular malformations, though each has practical limitations, including imaging artifacts that can complicate follow-up scans.15PubMed Central. Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas For brain AVMs, embolization is frequently a prelude to surgery or stereotactic radiosurgery rather than a standalone cure, because partially treated AVMs can sometimes recruit new feeding vessels.
Laser Treatment for Port-Wine Stains
Capillary malformations sit close to the skin surface, making them accessible to laser therapy. The pulsed dye laser is the most widely used and best-studied option. It works by selectively destroying the dilated blood vessels without damaging surrounding tissue.16PubMed Central. Laser treatment of port-wine stains
A large retrospective study of over 800 patients with port-wine stains found that the overall response rate was about 70%, but outcomes depended heavily on when treatment began and where the stain was located. Patients treated before age one had the highest response rate, at roughly 94%, while those treated after age 50 saw results in only about a quarter of cases. Location mattered too: stains on the temple responded best, while those on the limbs cleared the least. Lesions that had thickened or become nodular over time were significantly harder to treat than flat, red patches.17PubMed Central. Treatment of port wine stains with pulsed dye laser: a retrospective study of 848 cases in Shandong Province, People’s Republic of China The practical takeaway is straightforward: earlier treatment tends to produce better results, and waiting years can narrow the window of benefit.
Targeted Drug Therapies
The biggest shift in vascular malformation treatment over the past decade has been the arrival of drugs that target the same genetic pathways driving the lesions. Because many malformations are fueled by overactive PI3K/AKT/mTOR signaling, drugs already developed for cancer that block this pathway have found a new purpose.
Sirolimus (also known as rapamycin), an mTOR inhibitor originally used to prevent organ-transplant rejection, was one of the first to be tested. A systematic review covering 71 patients found that sirolimus produced partial remission in the majority across a range of malformation types, including lymphatic, venolymphatic, and combined capillary-lymphatic-venous malformations.18PubMed. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review A prospective study in patients with extensive slow-flow malformations that had failed conventional treatments confirmed that sirolimus was effective and generally well tolerated.19PubMed Central. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study
More recently, alpelisib, a PI3K-alpha-selective inhibitor initially approved for certain breast cancers, has shown striking results. In one cohort of 38 patients treated for more than three months, over 90% showed improvement in malformation-related symptoms, and about 70% of those with visible lesions saw their appearance improve. Notably, most of the responders did not have PROS, suggesting the drug’s benefit extends beyond the narrow population it was initially tested in.20PubMed Central. Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes Another study of alpelisib in patients with PROS found that about 38% achieved at least a 20% reduction in target lesion volume within six months of starting treatment.21PubMed. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS) A separate group reported radiological improvement in the majority of patients, along with pain relief and better quality of life, even in malformations harboring different PIK3CA and TIE2 mutations.22PubMed Central. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
These drugs are not cures. Malformations tend to regrow if the medication is stopped. But for patients with large, painful, or inoperable lesions, targeted therapy can significantly shrink the malformation, reduce pain, and improve day-to-day function in ways that sclerotherapy or surgery alone could not achieve.
Localized Intravascular Coagulopathy
One underappreciated complication of venous malformations is a clotting disorder called localized intravascular coagulopathy, or LIC. Blood pooling inside the dilated veins triggers slow, ongoing clot formation. This uses up clotting factors, particularly fibrinogen, and generates elevated levels of D-dimer, a breakdown product of blood clots. LIC has been observed in roughly 42% of patients with venous malformations.23PubMed Central. Elevated D-dimer Level is Diagnostic for Venous Malformations
Clinically, LIC shows up as chronic pain, swelling, and the formation of hard calcified nodules called phleboliths that can sometimes be felt through the skin. Large or deep venous malformations are at higher risk, and those affecting the limbs are especially prone to severe LIC where fibrinogen levels drop dangerously low.24PubMed Central. Association of localized intravascular coagulopathy with venous malformations The real danger is that severe LIC can escalate to disseminated intravascular coagulopathy (DIC), a life-threatening systemic clotting crisis. This is especially relevant before surgery: any procedure on a venous malformation with active LIC can trigger DIC if the coagulopathy is not treated first. Low-molecular-weight heparin is used both to manage the chronic pain of LIC and to prevent this escalation.25PubMed. Localized intravascular coagulation in venous malformations: A system review
Growth During Puberty and Pregnancy
Vascular malformations are present at birth, but they do not always stay the same size. Many are nearly invisible in infancy and become more apparent as the child grows. The sharpest changes tend to happen during hormonal shifts. A study comparing progression rates in children versus adolescents found that venous malformations were far more likely to enlarge during adolescence: about 61% of adolescents experienced progression, compared with roughly 23% of younger children, a relative risk of about 2.6.26PubMed. Venous malformation: risk of progression during childhood and adolescence Research examining the tissue itself has confirmed that hormone receptors are present in vascular malformations, lending biological plausibility to the clinical pattern.27Plastic and Reconstructive Surgery. Expression of Androgen, Estrogen, Progesterone, and Growth Hormone Receptors in Vascular Malformations
Pregnancy is another well-known trigger. The combination of rising hormone levels and increased blood volume can cause rapid expansion of previously stable malformations. For high-flow AVMs, this can be particularly dangerous. Case reports document extracranial AVMs rupturing during pregnancy as hormonal changes drive aggressive progression.28PubMed Central. Extracranial Arteriovenous Malformations Rupture in Pregnancy Women with known AVMs should discuss reproductive planning with their vascular team so that monitoring and, if needed, intervention can be arranged before a crisis occurs.
Living with a Vascular Malformation
The physical burden of vascular malformations gets most of the medical attention, but the psychological toll is substantial and often overlooked. A systematic review and meta-analysis found that patients with vascular malformations scored lower than the general population on standardized measures of both bodily pain and mental health.29PubMed Central. Vascular Malformations and Health-Related Quality of Life: A Systematic Review and Meta-analysis Separate research in patients with congenital vascular malformations found that roughly 13% had clinically relevant psychological distress and 15% had significant somatic distress, with higher distress scores linked to worse physical and mental health across virtually every measured domain.30Journal of Vascular Surgery: Venous and Lymphatic Disorders. Quality of life in patients with congenital vascular malformations
Pain is the single most common complaint. In patients with combined vascular malformations of the lower limb, pain was reported as a major issue in 88% of cases.31Clinics in Plastic Surgery. Management of Combined Vascular Malformations The pain comes from multiple sources: venous congestion creates a heavy, aching feeling; thrombosis within the malformation causes acute episodes; and malformations near joints can cause stiffness and limited movement. Chronic pain drives much of the depression and functional limitation patients experience, making pain management a core part of any treatment plan rather than an afterthought. Compression garments, anticoagulation for LIC-related pain, sclerotherapy to reduce lesion volume, and targeted medications all have roles to play depending on the individual situation.